Journal
BIPOLAR DISORDERS
Volume 15, Issue 1, Pages 1-44Publisher
WILEY
DOI: 10.1111/bdi.12025
Keywords
bipolar; CANMAT; depression; guidelines; mania; treatment
Categories
Funding
- AstraZeneca
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Canadian Network for Mood and Anxiety Treatments
- Eli Lilly Co.
- GlaxoSmithKline
- Janssen
- Michael Smith Foundation for Health Research
- Novartis
- Pfizer
- Ranbaxy
- Servier
- Stanley Foundation
- Lundbeck
- St. Jude Medical, Inc.
- CIHR
- NARSAD
- OMHF
- POGRS
- Apotex
- Biovail
- Wyeth
- AstraZeneca Canada
- BrainCells, Inc.
- Eli Lilly Canada
- Lundbeck Canada
- Pfizer Canada
- PSI Foundation
- Janssen-Ortho
- Organon
- Oryx
- Wythe-Ayerst
- FRSQ
- RSMQ
- Merck-Frosst
- Stanley Medical Research Institute
- Genome Quebec
- Nova Scotia Health Research Foundation
- Neuroscience Research Fund (Eli Lilly Canada)
- Cephalon
- Canadian Psychiatric Association
- Ontario Mental Health Foundation
- NCE AllerGen, Inc.
- Scottish Rite Foundation
- NIMH
- Shire
- Forest
- Sepracor
- Physicians' Postgraduate Press
- CME Outfitters
- Otsuka
- BCI
- Shering-Plough
- Takeda
- Coast Capital Depression Research Fund/UBC Institute of Mental Health
- Father Sean O'Sullivan Research Centre
- Stanley Medical Research Foundation
- CAPES
- FAPESP
- CNPq
- National Institutes of Mental Health
- Korea Healthcare Technology Research and Development Project
- Ministry of Health and Welfare of Korea
- Netherlands Organisation for Health Research and Development
- European Union
- MBF
- NHMRC
- Beyond Blue
- Geelong Medical Research Foundation
- Mayne Pharma
Ask authors/readers for more resources
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, ODonovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2012: 00: 000000. (C) 2012 John Wiley & Sons A/S.Published by Blackwell Publishing Ltd. The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first-line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first-line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first-line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second-line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not-recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long-acting injection, and adjunctive ziprasidone continue to be first-line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third-line options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available